Fox Chase Cancer Center | Strategic Alliance Partners

SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced a strategic partnership with Fox Chase Cancer Center.

Researchers discovered that the oncogene ERG triggers cancer by reprogramming prostate basal cells.

T-cell redirecting therapies can be safely monitored within the home of patients, limiting hospital visits according to researchers at Fox Chase.

Rashmi Khanal, MD , of Fox Chase Cancer Center discusses how TIL therapy can give patients with aggressive disease more hope for the future.

Effectiveness of prostate cancer drugs potentially tied to ancestry according to new research data.

Fox Chase Cancer Center’s Namrata ‘Neena’ Vijayvergia, MD, an expert in gastrointestinal cancers and rare NETs, was recently recognized by two NET advocacy groups for her contributions to the field.

A new method enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

The NAPBC has renewed Fox Chase Cancer Center’s accreditation, making it the sixth consecutive time Fox Chase has been honored with this distinction.

Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts.

Genetic testing could help determine differences between rare forms of kidney cancer.

Richard Bleicher, MD, FACS, discusses using a novel method to analyze tumor growth rates.

New research from Fox Chase Cancer Center uncovers mechanisms of breast cancer resistance to CDK4/6 inhibitors and offers innovative treatment strategies.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene that may play an important role in colon cancer.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

Fox Chase Cancer Center Researcher secures funding to investigate toxicity reduction in bladder cancer treatment.

Fox Chase Cancer Center researcher Adria Hasan honored with scholar-in-training award from American Association for Cancer Research.

Jonathan Chernoff, MD, PhD, Cancer Center Director of Fox Chase Cancer Center, was recently elected to the Association of American Physicians (AAP).

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Removing and testing more lymph nodes during surgery was associated with more accurate staging and better survival rates for patients with colon cancer.

Results from a study presented by Fox Chase Cancer Center suggest that chemotherapy followed by local excision is a promising treatment option for patients with node-negative low rectal cancer.

Jaye Gardiner, PhD, postdoctoral fellow at Fox Chase Cancer Center to receive a grant from the nonprofit Uplifting Athletes during its Young Investigators Draft.

Fox Chase Cancer Center’s Biosample Repository Facility was recently awarded reaccreditation by the College of American Pathologists based on the results of an on-site inspection.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Researchers at Fox Chase Cancer Center published 2 reviews on the role of AKT, also known as protein kinase B, in the development and treatment of cancer.

Erin K. Tagai, PhD, MPH, has received a grant from the Prevent Cancer Foundation to fund development of a ChatBot for patients receiving genetic testing results.

Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.